Novel classes of potential MBL inhibitors were investigated. A concerted effort of computational and synthetic chemistry was carried out and new compounds were identified. Researchers studied their structure-activity relationship and selected drug-like properties, such as solubility, chemical stability and toxicity. The initial hit NF1810 was optimized providing a broad spectrum inhibitor. However, specific solubility and toxicity issues need to be solved in order to identify inhibitors suitable for in vivo evaluation. No MBL inhibitors have been approved in therapy today. Novel hits were identified in this project and their further optimization could lead to the selection of preclinical candidates to establish the proof-of-concept for novel combination therapies (antibiotics plus MBL inhibitors) for the treatment of lung infections in CF patients.